Results 1 to 10 of about 373,840 (223)

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2 [PDF]

BMC Infectious Diseases, 2021
Background The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health. The use of antiviral drugs in patients with this disease have triggered people’s attentions.
Jingyuan Liu, Chunjing Du, Lin Pu, Pan Xiang, Haofeng Xiong, Wen Xie, Zhihai Chen, Ang Li   +7 more
doaj   +2 more sources

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. [PDF]

Cancer Discov, 2022
We conducted a randomized phase 3 trial to evaluate whether adjuvant pembrolizumab for one year (648 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison to high-dose interferon alfa-2b for one year or ipilimumab for ...
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A.   +30 more
europepmc   +2 more sources

Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.

JAMA Netw Open, 2023
Key Points Question Does interferon alfa enhance the clinical benefits of temozolomide as the first-line treatment in patients with newly diagnosed high-grade glioma (HGG)? Findings In this phase 3 randomized clinical trial study of 199 patients with HGG,
Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, Li J, Sai K, Xi S, Ouyang H, Liu M, Li X, Li Z, Ni X, Cao X, Li C, Wu S, Du X, Su J, Xue X, Wang Y, Li G, Qin Z, Yang H, Zhou T, Liu J, Hu X, Wang J, Jiang X, Lin F, Zhang X, Ke C, Lv X, Lv Y, Hu W, Zeng J, Chen Z, Zhong S, Wang H, Chen Y, Zhang J, Li D, Mou Y, Chen Z.   +43 more
europepmc   +2 more sources

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. [PDF]

Cancers (Basel), 2020
Interferon alfa was first used in the treatment of myeloproliferative neoplasms (MPNs) over 30 years ago. However, its initial use was hampered by its side effect profile and lack of official regulatory approval for MPN treatment.
How J, Hobbs G.
europepmc   +2 more sources

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. [PDF]

Blood Adv
Key Points • Treatment with ruxolitinib and interferon alfa-2a is well tolerated with anemia as the main cause for dose reduction.• Treatment with ruxolitinib and interferon alfa-2a elicits high rates of hematologic and molecular response.
Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H.   +13 more
europepmc   +2 more sources

Interferon Alfa-N1 [PDF]

Definitions, 2020
A highly purified alpha interferon produced by a human lymphoid cell line. Interferon alpha-n1 consists of multiple alpha interferon subtypes, at least two of which are glycosylated.
Interferon Alfa-N
openaire   +2 more sources

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations [PDF]

Therapeutic Advances in Hematology
Pegylated interferons alfa are increasingly used in patients with myeloproliferative neoplasms (MPN) due to their potential disease-modifying effect. Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic ...
Axel Rüfer, Christoph Brand, Andrea de Gottardi, Stefan Fischli, Ralph Melzer, Urs Odermatt, Walter A. Wuillemin, Sacha S. Zeerleder   +7 more
doaj   +2 more sources

Interferon Alfa-N3 [PDF]

Definitions, 2020
A formulated therapeutic analog of the endogenous alpha interferon containing multiple interferon species with antiviral and antitumor properties. Interferons bind to specific cellsurface receptors, leading to the transcription and translation of genes ...
openaire   +2 more sources

Episcleritis in a patient with mucosal melanoma treated with interferon alfa-2b and radiotherapy: a case report [PDF]

Journal of Medical Case Reports, 2018
Background Mucosal melanoma of the head and neck is a rare malignant tumor associated with a poor prognosis. Surgery, chemotherapy, radiotherapy, and biotherapy are common strategies for treating mucosal melanoma of the head and neck.
Li Yang, Shaofei Ji, Liping Wang, Yi Zhang   +3 more
doaj   +2 more sources

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. [PDF]

BMC Pharmacol Toxicol, 2018
Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between ...
Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, Góes ACMA, Batoreu NM, Maia MLS, Albuquerque EM, Matos DCS, Saura PL.   +11 more
europepmc   +2 more sources